epirubicin + cyclophosphamide + paclitaxel + carrelizumab

This is a combination regimen consisting of three chemotherapeutic agents—epirubicin, cyclophosphamide, and paclitaxel—together with carrelizumab (also known as camrelizumab), a humanized anti-PD-1 monoclonal antibody. - **Epirubicin** is an anthracycline antibiotic that intercalates DNA and inhibits topoisomerase II, leading to inhibition of DNA replication and RNA synthesis. - **Cyclophosphamide** is an alkylating agent that crosslinks DNA strands, preventing cell division and leading to apoptosis in rapidly dividing cells. - **Paclitaxel** is a taxane-class chemotherapeutic that stabilizes microtubules, inhibiting their disassembly during mitosis and thereby blocking cell division[6][8][10]. - **Carrelizumab (camrelizumab)** is a programmed death 1 (PD-1) immune checkpoint inhibitor; it blocks the interaction between PD-1 on T cells and its ligands PD-L1/PD-L2 on tumor cells or other immune cells, enhancing T-cell mediated antitumor responses[5][7]. This combination leverages both cytotoxic chemotherapy to directly kill tumor cells and immunotherapy to enhance the host's immune response against cancer. It has been studied in various solid tumors including non-small cell lung cancer (NSCLC), esophageal squamous cell carcinoma, prostate cancer, among others[2][3][4][5].

Other names

camrelizumab + cyclophosphamide + epirubicin + paclitaxel